Prostate-specific membrane antigen-targeted photodynamic therapy induces rapid cytoskeletal disruption
- PMID: 20452720
- PMCID: PMC3201799
- DOI: 10.1016/j.canlet.2010.04.003
Prostate-specific membrane antigen-targeted photodynamic therapy induces rapid cytoskeletal disruption
Abstract
Prostate-specific membrane antigen (PSMA), an established enzyme-biomarker for prostate cancer, has attracted considerable attention as a target for imaging and therapeutic applications. We aimed to determine the effects of PSMA-targeted photodynamic therapy (PDT) on cytoskeletal networks in prostate cancer cells. PSMA-targeted PDT resulted in rapid disruption of microtubules (alpha-/beta-tubulin), microfilaments (actin), and intermediate filaments (cytokeratin 8/18) in the cytoplasm of LNCaP cells. The collapse of cytoplasmic microtubules and the later nuclear translocation of alpha-/beta-tubulin were the most dramatic alternation. It is likely that these early changes of cytoskeletal networks are partly involved in the initiation of cell death.
Copyright 2010 Elsevier Ireland Ltd. All rights reserved.
Conflict of interest statement
Dr. Berkman is the inventor of a patent on the PSMA inhibitor described in this report and presently serves as the CSO of Cancer Targeted Technology.
Figures
Similar articles
-
In vitro targeted photodynamic therapy with a pyropheophorbide--a conjugated inhibitor of prostate-specific membrane antigen.Prostate. 2009 May 1;69(6):585-94. doi: 10.1002/pros.20909. Prostate. 2009. PMID: 19142895 Free PMC article.
-
Targeted photodynamic therapy for prostate cancer: inducing apoptosis via activation of the caspase-8/-3 cascade pathway.Int J Oncol. 2010 Apr;36(4):777-84. doi: 10.3892/ijo_00000553. Int J Oncol. 2010. PMID: 20198319
-
Alterations in microtubules, intermediate filaments, and microfilaments induced by microcystin-LR in cultured cells.Toxicol Pathol. 1995 May-Jun;23(3):326-37. doi: 10.1177/019262339502300309. Toxicol Pathol. 1995. PMID: 7659955
-
Joining actions: crosstalk between intermediate filaments and actin orchestrates cellular physical dynamics and signaling.Sci China Life Sci. 2019 Oct;62(10):1368-1374. doi: 10.1007/s11427-018-9488-1. Epub 2019 May 14. Sci China Life Sci. 2019. PMID: 31098891 Review.
-
Prostate-specific membrane antigen from diagnostic to therapeutic target: radionuclide therapy comes of age in prostate cancer.BJU Int. 2017 Sep;120(3):310-312. doi: 10.1111/bju.13871. Epub 2017 May 2. BJU Int. 2017. PMID: 28380282 Review. No abstract available.
Cited by
-
Graphdiyne Oxide-Mediated Photodynamic Therapy Boosts Enhancive T-Cell Immune Responses by Increasing Cellular Stiffness.Int J Nanomedicine. 2023 Feb 15;18:797-812. doi: 10.2147/IJN.S392998. eCollection 2023. Int J Nanomedicine. 2023. PMID: 36814858 Free PMC article.
-
Photodynamic therapy for prostate cancer: Recent advances, challenges and opportunities.Front Oncol. 2022 Sep 23;12:980239. doi: 10.3389/fonc.2022.980239. eCollection 2022. Front Oncol. 2022. PMID: 36212416 Free PMC article. Review.
-
The use of advanced imaging in guiding the further investigation and treatment of primary prostate cancer.Cancer Imaging. 2022 Sep 3;22(1):45. doi: 10.1186/s40644-022-00481-3. Cancer Imaging. 2022. PMID: 36057766 Free PMC article. Review.
-
Advances in PSMA-targeted therapy for prostate cancer.Prostate Cancer Prostatic Dis. 2022 Mar;25(1):11-26. doi: 10.1038/s41391-021-00394-5. Epub 2021 May 28. Prostate Cancer Prostatic Dis. 2022. PMID: 34050265 Review.
-
PSMA-targeting agents for radio- and fluorescence-guided prostate cancer surgery.Theranostics. 2019 Sep 20;9(23):6824-6839. doi: 10.7150/thno.36739. eCollection 2019. Theranostics. 2019. PMID: 31660071 Free PMC article. Review.
References
-
- Allison RR, Downie GH, Cuenca R, Hu XH, Childs CJ, Sibata CH. Photosensitizers in clinical PDT. Photodiagnosis and Photodynamic Therapy. 2004;1:27–42. - PubMed
-
- Sharman WM, van Lier JE, Allen CM. Targeted photodynamic therapy via receptor mediated delivery systems. Adv Drug Deliv Rev. 2004;56:53–76. - PubMed
-
- Detty MR, Gibson SL, Wagner SJ. Current clinical and preclinical photosensitizers for use in photodynamic therapy. Journal of medicinal chemistry. 2004;47:3897–3915. - PubMed
-
- Berg K, Selbo PK, Weyergang A, Dietze A, Prasmickaite L, Bonsted A, Engesaeter BO, Angell-Petersen E, Warloe T, Frandsen N, Hogset A. Porphyrin-related photosensitizers for cancer imaging and therapeutic applications. J Microsc. 2005;218:133–147. - PubMed
-
- Moore CM, Pendse D, Emberton M. Photodynamic therapy for prostate cancer--a review of current status and future promise. Nature clinical practice. Urology. 2009;6:18–30. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous
